AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2239724 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary ventricular fibrillation (VF)
Number of subjects: 5839
Study 2239724 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no primary VF)
Number of subjects: 5839
Study 364258 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian version of the Feingold elimination diet
Number of subjects: 16
Study 31289971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth whitening with a photo-activated whitening gel
Number of subjects: 60
Study 31289971 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 31744060 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggplant powder (1.2 g/day; 2.3 mg of ACh/day) for 12 weeks
Number of subjects: 100
Study 31744060 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 100
Study 28915283 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal facial serum containing HA, Proxylane (C‐Xyloside), purple rice extract, and dipotassium glycyrrhizate
Number of subjects: 59
Study 25543296 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine varnish 2%
Number of subjects: 35
Study 25543296 — intervention group
Group type: EXPERIMENTAL
Intervention: c-PACT (curcumin at 1.5 mg.mL(‐1) with blue LED light)
Number of subjects: 35
Study 25543296 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 35
Study 23112214 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced starch (HES, 130/0.4, 6%) solution
Number of subjects: 50
Study 23112214 — intervention group
Group type: COMPARATOR
Intervention: Balanced crystalloid solution
Number of subjects: 50
Study 20924633 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of G-CSF (lenograstim, 100 μg)
Number of subjects: 30
Study 20924633 — intervention group
Group type: COMPARATOR
Intervention: G-CSF (100 μg) administered every other day
Number of subjects: 30
Study 19183141 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine (Paxil)
Number of subjects: 56
Study 19183141 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean blood alcohol concentration of 0.10%)
Number of subjects: 56
Study 19183141 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 56
Study 19183141 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (no alcohol)
Number of subjects: 56
Study 16995813 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day, orally)
Number of subjects: 0
Study 16995813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15316642 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg midazolam
Number of subjects: 174
Study 15316642 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl
Number of subjects: 174
Study 15316642 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 174
Study 11564852 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research partnership
Number of subjects: 0
Study 11564852 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitating factors identified by Board members
Number of subjects: 0
Study 11564852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing challenges identified by Board members
Number of subjects: 0
Study 9292360 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV awareness training programme
Number of subjects: 65
Study 9292360 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 65
Study 8487239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with MPA 5.0 mg for 12 days of each 25-day cycle plus CEE 0.625 mg daily
Number of subjects: 36
Study 8487239 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with MPA 2.5 mg daily for 12 treatment cycles plus CEE 0.625 mg daily
Number of subjects: 36
Study 8487239 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with MPA 5.0 mg daily for 12 treatment cycles plus CEE 0.625 mg daily
Number of subjects: 36
Study 8487239 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (sequential and continuous)
Number of subjects: 36
Study 3302998 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam, 20 mg daily, orally for 10 days
Number of subjects: 40
Study 3302998 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally for 10 days
Number of subjects: 40
Study 29227377 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg and Amiloride 2.5 mg once a day
Number of subjects: 730
Study 29227377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 27996320 — intervention group
Group type: COMPARATOR
Intervention: CL alone
Number of subjects: 12
Study 27996320 — intervention group
Group type: EXPERIMENTAL
Intervention: CL+snack
Number of subjects: 12
Study 24548581 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental concern scores (CFQ)
Number of subjects: 77
Study 24548581 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental responsibility scores (CFQ)
Number of subjects: 77
Study 24548581 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in CFQ subscale scores
Number of subjects: 77
Study 22237061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (200,000 IU/week for 3 weeks)
Number of subjects: 52
Study 22237061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20691067 — intervention group
Group type: EXPERIMENTAL
Intervention: Staying healthy at work
Number of subjects: 0
Study 20691067 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 17888078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (60-min infusions)
Number of subjects: 60
Study 17888078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (30-min infusions)
Number of subjects: 60
Study 17888078 — intervention group
Group type: COMPARATOR
Intervention: Oral lacosamide (control)
Number of subjects: 60
Study 16826019 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 431
Study 16826019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (VPA)
Number of subjects: 431
Study 16826019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesson context by field site
Number of subjects: 431
Study 16826019 — intervention group
Group type: COMPARATOR
Intervention: Coed vs girls-only classes
Number of subjects: 431
Study 16826019 — intervention group
Group type: COMPARATOR
Intervention: Outdoor lessons vs indoor lessons
Number of subjects: 431
Study 12538372 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 20 mg bd i.v.
Number of subjects: 195
Study 12538372 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg bd i.v.
Number of subjects: 195
Study 12538372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 11515622 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Number of subjects: 71
Study 11515622 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Number of subjects: 71
Study 11515622 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori cured patients
Number of subjects: 71
Study 11515622 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori persisting infection
Number of subjects: 71
Study 8890678 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (intravenous doses)
Number of subjects: 47
Study 1900687 — intervention group
Group type: EXPERIMENTAL
Intervention: ACNU + Futraful (FT)
Number of subjects: 2456
Study 1900687 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + FT
Number of subjects: 2456
Study 1900687 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM + FT
Number of subjects: 2456
Study 1900687 — intervention group
Group type: COMPARATOR
Intervention: FT alone
Number of subjects: 2456
Study 6225313 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (225 mg)
Number of subjects: 24
Study 6225313 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (150 mg)
Number of subjects: 24
Study 31425397 — intervention group
Group type: EXPERIMENTAL
Intervention: Data to Care (D2C) model implementation
Number of subjects: 3
Study 29551533 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (7 DU)
Number of subjects: 637
Study 29551533 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (all doses)
Number of subjects: 637
Study 29551533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 26951571 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of directly observed once‐weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP‐DOT)
Number of subjects: 6232
Study 26951571 — intervention group
Group type: COMPARATOR
Intervention: 9 months of daily self‐administered isoniazid (maximum dose, 300 mg; 9H‐SAT)
Number of subjects: 6232
Study 25011612 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise referral scheme to a group physical activity program at sports facilities, duration not specified.
Number of subjects: 0
Study 25011612 — intervention group
Group type: COMPARATOR
Intervention: Information about physical activity benefits and ways to increase it safely (Control Group).
Number of subjects: 0
Study 21602517 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of ketoconazole (a potent CYP3A4 inhibitor)
Number of subjects: 0
Study 21602517 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of erythromycin (a moderate CYP3A4 inhibitor)
Number of subjects: 0
Study 21602517 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of rifampin (a potent CYP3A4 inducer)
Number of subjects: 0
Study 21602517 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib alone and in combination with ketoconazole, erythromycin, or rifampin
Number of subjects: 0
Study 19105762 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 17501997 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (VABB with 11G, 24 cores)
Number of subjects: 107
Study 17501997 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended protocol (VABB with 11G, 96 cores)
Number of subjects: 107
Study 17501997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 107
Study 17501997 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended protocol
Number of subjects: 107
Study 15470331 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (300 mg 3 times daily)
Number of subjects: 12
Study 11394559 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered, computer‐based intervention delivered in 15 brief weekly segments
Number of subjects: 277
Study 11394559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 277
Study 11394559 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered, computer‐based intervention
Number of subjects: 277
Study 9743881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 45
Study 9743881 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 45
Study 8066102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intracervical application of PGE2 gel
Number of subjects: 32
Study 8066102 — intervention group
Group type: COMPARATOR
Intervention: Repeated intracervical application of PGE2 gel (2 h apart)
Number of subjects: 32
Study 2713518 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with adriamycin, vincristine and methotrexate (AVM), loco-regional radiotherapy and maintenance chemotherapy with vincristine, cyclophosphamide and 5 fluorouracil (VCF)
Number of subjects: 210
Study 2713518 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced protocol with five drugs: adriamycin, vincristine, cyclophosphamide, methotrexate, 5 FU (AVCMF)
Number of subjects: 210
Study 2713518 — intervention group
Group type: EXPERIMENTAL
Intervention: Same schedule AVCMF, AVM, VCF with different radiotherapy schedule
Number of subjects: 210
Study 2713518 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone with castration for pre-menopausal women (historical control group T)
Number of subjects: 210
Study 2713518 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with adriamycin, vincristine and methotrexate (AVM)
Number of subjects: 210
Study 30209576 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a plasma concentration of 1000 ng/mL
Number of subjects: 80
Study 30209576 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 30209576 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 20 mg as a rescue antiemetic
Number of subjects: 80
Study 30209576 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol group
Number of subjects: 80
Study 30209576 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study 26821074 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve M-16V supplementation
Number of subjects: 21
Study 26821074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25904602 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP concentration (highest quintile ≥7149.4 nmol/L)
Number of subjects: 885
Study 25904602 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D (highest group ≥100 nmol/L)
Number of subjects: 885
Study 25904602 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D (lowest group <25 nmol/L)
Number of subjects: 885
Study 23343312 — intervention group
Group type: EXPERIMENTAL
Intervention: Social health program 'Sumida TAKE10!' (n=57), educational program incorporating 'TAKE10!® for Older Adults', once every 2 weeks for 3 months
Number of subjects: 92
Study 23343312 — intervention group
Group type: EXPERIMENTAL
Intervention: Social health program 'Sumida TAKE10!' (n=57)
Number of subjects: 92
Study 23343312 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 92
Study 20007305 — intervention group
Group type: COMPARATOR
Intervention: No-choice condition
Number of subjects: 303
Study 20007305 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal-choice condition
Number of subjects: 303
Study 20007305 — intervention group
Group type: EXPERIMENTAL
Intervention: At-meal-choice condition
Number of subjects: 303
Study 20007305 — intervention group
Group type: COMPARATOR
Intervention: No-choice condition (high-reactant children)
Number of subjects: 303
Study 20007305 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 303
Study 19087569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 31
Study 19087569 — intervention group
Group type: COMPARATOR
Intervention: Control (no HT)
Number of subjects: 31
Study 16980806 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily infant massage therapy by orphanage staff or volunteers for an average of 53 days
Number of subjects: 0
Study 16980806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14626640 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and micronutrient combination supplementation (including vitamin B12 and B6)
Number of subjects: 0
Study 14626640 — intervention group
Group type: EXPERIMENTAL
Intervention: Flour fortification with vitamins B (folate, B12, B2, B6)
Number of subjects: 0
Study 11099674 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis (using Amicus, Autopheresis‐C, and CS‐3000)
Number of subjects: 10
Study 8797135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg oral dose)
Number of subjects: 15
Study 8797135 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg oral dose)
Number of subjects: 15
Study 8797135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1319961 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 22
Study 1319961 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 22
Study 1319961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6241770 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ng hepatitis B surface antigen aluminium‐adsorbed vaccine, 3 doses of 40 micrograms over 6 months
Number of subjects: 0
Study 6241770 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine prior to surgery
Number of subjects: 0
Study 31190122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum PTH levels
Number of subjects: 5108
Study 31190122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PTH of 0 pg/mL
Number of subjects: 5108
Study 31190122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PTH of 69 pg/mL
Number of subjects: 5108
Study 31190122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PTH of 58 pg/mL
Number of subjects: 5108
Study 29203274 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular Education Program for Children with Epilepsy and Their Parents
Number of subjects: 184
Study 29203274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not participating in the modular education program)
Number of subjects: 184
Study 26951097 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 permanent brachytherapy (PBT)
Number of subjects: 90
Study 26951097 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 90
Study 24768303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Group (n=75)
Number of subjects: 150
Study 24768303 — intervention group
Group type: COMPARATOR
Intervention: Landmark Group (n=75)
Number of subjects: 150
Study 22712818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 16
Study 22712818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20088690 — intervention group
Group type: EXPERIMENTAL
Intervention: Face masks with hand hygiene
Number of subjects: 1437
Study 20088690 — intervention group
Group type: EXPERIMENTAL
Intervention: Face masks alone
Number of subjects: 1437
Study 20088690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1437
Study 18514105 — intervention group
Group type: EXPERIMENTAL
Intervention: OMS103HP (investigational drug product containing ketoprofen, amitriptyline, and oxymetazoline)
Number of subjects: 0
Study 18514105 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 16252346 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel method using joint features of fractal dimension and entropies of texture edge co-occurrence matrix based on ultrasound images.
Number of subjects: 36
Study 16252346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher linear classifier and support vector machine.
Number of subjects: 36
Study 16252346 — intervention group
Group type: COMPARATOR
Intervention: Control group of normal human volunteers.
Number of subjects: 36
Study 12032039 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.2 mg/kg followed by infusion at a rate of 2 mg.kg(‐1).h(‐1)
Number of subjects: 22
Study 12032039 — intervention group
Group type: COMPARATOR
Intervention: IV midazolam 5 mg
Number of subjects: 22
Study 9706861 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% metronidazole sustained release gel
Number of subjects: 18
Study 9706861 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% tetracycline ointment
Number of subjects: 18
Study 9706861 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling and root planing
Number of subjects: 18
Study 7604427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 24
Study 7604427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2204251 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene (Clomid, Merrell)
Number of subjects: 118
Study 2204251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 23137 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of aspirin
Number of subjects: 30
Study 23137 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of ethanol
Number of subjects: 30
Study 23137 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of indomethacin
Number of subjects: 30
Study 23137 — intervention group
Group type: EXPERIMENTAL
Intervention: Deionized water at 65°C
Number of subjects: 30
Study 23137 — intervention group
Group type: EXPERIMENTAL
Intervention: Deionized water at 20°C
Number of subjects: 30
Study 23137 — intervention group
Group type: EXPERIMENTAL
Intervention: 9α‐fludrocortisone
Number of subjects: 30
Study 31151363 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24
Study 31151363 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 24
Study 29624628 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained (full-crown abutment [FCA])
Number of subjects: 32
Study 29624628 — intervention group
Group type: COMPARATOR
Intervention: Cemented (zirconia crown [ZrC])
Number of subjects: 32
Study 28446646 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 117
Study 28446646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 22528757 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg)
Number of subjects: 80
Study 22528757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23021318 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids N Fitness(©), a 6-week program providing 45min of structured physical activity and a 45min nutrition education class for parents and children
Number of subjects: 251
Study 21921285 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with tamoxifen (20 mg/d for 5 years)
Number of subjects: 431
Study 21921285 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy with tamoxifen (20 mg/d for 5 years)
Number of subjects: 431
Study 21921285 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with tamoxifen
Number of subjects: 431